Actavis faces New York antitrust lawsuit over Namenda XR switch
This article was originally published in Scrip
Executive Summary
New York Attorney General Eric Schneiderman filed a lawsuit against Actavis to stop the "forced switch" of Alzheimer's disease patients from twice-daily Namenda (memantine) to once-daily Namenda XR several months before generic memantine becomes available in mid-2015.